Compare · AZN vs BFRI
AZN vs BFRI
Side-by-side comparison of AstraZeneca PLC (AZN) and Biofrontera Inc. (BFRI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both AZN and BFRI operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- AZN is the larger of the two at $277.21B, about 25597.1x BFRI ($10.8M).
- AZN has been more active in the news (22 items in the past 4 weeks vs 6 for BFRI).
- AZN has more recent analyst coverage (25 ratings vs 3 for BFRI).
- Company
- AstraZeneca PLC
- Biofrontera Inc.
- Price
- -
- -
- Market cap
- $277.21B
- $10.8M
- 1M return
- +5.89%
- -
- 1Y return
- +100.84%
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2026
- 2021
- News (4w)
- 22
- 6
- Recent ratings
- 25
- 3
AstraZeneca PLC
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Biofrontera Inc.
Biofrontera Inc., a biopharmaceutical company, develops and provides dermatological products for the treatment of skin diseases in the United States. It primarily develops therapies for non-melanoma skin cancer. It offers Ameluz, an aminolevulinic acid hydrochloride gel for the photodynamic therapy of actinic keratoses; and BF-RhodoLED, an LED lamp emitting red light for use in photodynamic therapy. The company was founded in 1997 and is based in Woburn, Massachusetts.
Latest AZN
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- SEC Form 6-K filed by AstraZeneca PLC
- Perioperative IMFINZI® (durvalumab) approved in the US in novel regimen with neoadjuvant enfortumab vedotin-ejfv for patients with muscle-invasive bladder cancer
- FDA Approval for KLYGEFA issued to ALEXION PHARM
- AstraZeneca awards $1.6 million for programs to improve access to healthcare for patients across the US
- Officer Sharma Mani was granted 1 units of Ordinary Shares, increasing direct ownership by 0.01% to 19,292 units (SEC Form 4)
- Gabelli Releases Agenda for 8th Annual Healthcare Symposium
- SEC Form 6-K filed by AstraZeneca PLC
Latest BFRI
- SEC Form 10-Q filed by Biofrontera Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Biofrontera Inc.
- Biofrontera Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Biofrontera Inc. Reports Strong Third Quarter 2026 Financial Results Driven by 30% Year-Over-Year Revenue Growth
- Biofrontera Inc. to Report Third Quarter 2026 Financial Results on November 13, 2026
- SEC Form 25-NSE filed by Biofrontera Inc.
- Biofrontera Submits Supplemental New Drug Application to FDA to Expand Ameluz® Red Light PDT to Actinic Keratoses on the Full Body
- Biofrontera Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Biofrontera Announces FDA Approval of Ameluz® Red Light PDT for the Treatment of Superficial Basal Cell Carcinoma
- SEC Form 10-Q filed by Biofrontera Inc.